Calcium-Phosphate Metabolism Disorders in Patients with Renal Failure Clinical Significance, Diagnosis and Treatment

1. Song L. Calcium and Bone Metabolism Indices. Adv Clin Chem. 2017;82:1-46. doi: 10.1016/bs.acc.2017.06.005. Epub 2017 Aug 7.10.1016/bs.acc.2017.06.005.Epub2017Aug7Open DOISearch in Google Scholar

2. Cunningham J, Locatelli F, Rodriguez M. Secondary Hyper-parathyroidism: Pathogenesis, Disease Progression, and Therapeutic Options. Clin J Am Soc Nephrol, 2011;6(4): 913-921.10.2215/CJN.0604071021454719Search in Google Scholar

3. Krivoshiev S., A.-M. Borissova. From Renal Osteodys-trophy to Senile Osteoporosis. J Bulg Soc Endocrinol. 2003,8(2),68-75.Search in Google Scholar

4. Edna D. Taniegra, M.D., Hyperparathyroidism. Am Fam Physician. 2004 Jan 15;69(2):333-339.Search in Google Scholar

5. Nitta K, Yajima A, Tsuchiya K. Management of Osteoporosis in Chronic Kidney Disease. Intern Med. 2017 Dec 15; 56(24): 3271-3276.10.2169/internalmedicine.8618-16579071229021477Search in Google Scholar

6. Krivoshiev, St, E. Katerdzhieva, Ts. Baldev et al. Vascular calcifications in patients with terminal chronic renal failure treated with prolonged hemodialysis. Roentgenology and Radiology, 1994, Suppl., 39-42.Search in Google Scholar

7. Martin, KJ, EA Gonzalez. Strategies to minimize bone disease in renal failure. Am J Kidney Dis, 38, 2001, 6, 1430-1436.10.1053/ajkd.2001.2928311728986Search in Google Scholar

8. Llach F., F. V Forero. Secondary Hyperparathyreoidism in chronic renal failure: pathogenic and clinical aspects. Am J Kidney dis, 2001;38(5), Suppl 5, S20-S33.10.1053/ajkd.2001.2811311689384Search in Google Scholar

9. Hsu, C.-Y., G. M. Ghertow. Elevations of serum phosphorus and potassium in mild to moderate chronic renal incufficiency. Nephrol Dial Transplant, 2002;17(6), 1419-1425.10.1093/ndt/17.8.141912147789Search in Google Scholar

10. Levey, A. S. Controlling the epidemic of cardiovascular disease in chronic renal disease:where do we start? Am. J. Kidney Dis., 1998;32(5), Suppl. 3, S5-S13.10.1053/ajkd.1998.v32.pm98204639820463Search in Google Scholar

11. Slatopolsky, E., A. Brown, A. Dusso. Phosphate control and osteodistrophy. Role of phosphorus in the pathogenesis of secondary hiperparathyreoidism. Am J Kidney Dis, 2001;37 (1), Suppl. 2, S54-S57.10.1053/ajkd.2001.2074011158862Search in Google Scholar

12. Coen, G., P. Ballanti, E. Bonucci et al. Taggi, Renal osteodys-trophy in predialysis and haemodialysis patients: comparison of histologic patternsand diagnostic predictivity of intact PTH. Nephron, 2002;91(1), 103-111.10.1159/00005761112021526Search in Google Scholar

13. Hercz, G. Regulation of bone remodeling: impact of novel therapies. Semin Dial, 2001;14(1),55-60.10.1046/j.1525-139x.2001.00015.x11208041Search in Google Scholar

14. Hampson, G, Vaja S, Evans C et al. Comparison of the humoral markers of bone turnover and bone mineral density in patients on haemodialsysis and continuous ambulatory peritoneal dialysis. Nephron, 2002;91(1), 94-102.10.1159/000057610Search in Google Scholar

15. Yamamoto, T, Ozono K, Miyauchi A et al. Role of advanced glycation end products in adynamic bone disease in patients with diabetic nephropathy. Am J Kidney Dis, 2001;38(4), Suppl. 1 S161-S164.10.1053/ajkd.2001.27428Search in Google Scholar

16. London, G. Cardiovascular disease in end stage renal failure: role of calcium-phosphate disturbances and hyperparathyreoidism. J. Nephrol, 2002;15(2), 209-210.Search in Google Scholar

17. Rao, D.S., M.S. Shih, R. Mohini. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N. Engl. J Med, 1993;328, 171-175.10.1056/NEJM199301213280304Search in Google Scholar

18. Giannini, S, D’Angelo A, Carraro G et al. Persistently increased bone turnover and low bone density in long-term survivors to kidney transplantation. Clin Nephrol., 2001;56(5), 353-363.Search in Google Scholar

19. Horwitz M. What medical options should be considered for the treatment of primary hyperparathyroidism? Clin Endocrinol. 2011;75(5):592-595.10.1111/j.1365-2265.2011.04050.xSearch in Google Scholar

20. Khan A., Bilezikian J., Kung A. et al. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2004;89: 3319-25.10.1210/jc.2003-030908Search in Google Scholar

21. Moe S, Drüeke T, Cunningham J et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;69(11):1945-53.10.1038/sj.ki.5000414Search in Google Scholar

22. [Guideline] National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42 (4 Suppl 3):S1-201.10.1016/S0272-6386(03)00905-3Search in Google Scholar

23. [Guideline] Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009,(113): S1-130.Search in Google Scholar

24. Chronic Kidney Disease, Article in Madscape, Pradeep Arora, MD Assistant Professor of Medicine, University of Buffalo State University of New York School of Medicine, july 2018.Search in Google Scholar

25. 25. Imaging in Secondary Hyperparathyroidism, Article in Madscape, Ali Nawaz Khan, MBBS, FRCS, FRCP, FRCR Consultant Radiologist and Honorary Professor, North Manchester General Hospital, nov. 2015.Search in Google Scholar

26. Sharma AK, Masterson R, Holt SG, Toussaint ND. Emerging role of high-resolution imaging in the detection of renal osteo-dystrophy. Nephrology (Carlton). 2016;21(10):801-11.10.1111/nep.1279027042945Search in Google Scholar

27. Henriques JC, De Melo Castilho JC, Jacobs R et al. Severe secondary hyperparathyroidism and panoramic radiography parameters. Clin Oral Investig. 2013 Jul 12.10.1007/s00784-013-1025-023846212Search in Google Scholar

28. Kidney Disease: Improving Global Outcomes (KDIGO) CKDMBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2017. 7:1-59.10.1016/j.kisu.2017.04.001634091930675420Search in Google Scholar

29. Eleanor Lederer, MD, FASN Professor of Medicine, Chief, Nephrology Division, Director, Nephrology Training Program, Director, Metabolic Stone Clinic, Kidney Disease Program, University of Louisville School of Medicine; Consulting Staff, Louisville Veterans Affairs Hospital, 2017.Search in Google Scholar

30. Andrew L. Lundquist; Sagar U. Nigwekar, Curr Opin Nephrol Hypertens. 2016;25(2):120-126.10.1097/MNH.0000000000000203Search in Google Scholar